Skip to content
Inciteful Med

The Biology of DM1: Understanding Your Genetic Report

Last updated:

Myotonic Dystrophy Type 1 (DM1) is caused by an abnormal expansion of CTG repeats in the DMPK gene. A repeat count of 50 or higher confirms a DM1 diagnosis. This genetic expansion creates toxic RNA that disrupts normal cell function across multiple organs.

Key Takeaways

  • • DM1 is caused by an abnormal expansion of CTG repeats in the DMPK gene on chromosome 19.
  • • A CTG repeat count of 50 or higher on your genetic report confirms a pathogenic diagnosis for DM1.
  • • The expanded gene creates toxic RNA that traps essential proteins, leading to a widespread cellular dysfunction known as spliceopathy.
  • • Genetic anticipation means the CTG repeat count can grow larger in future generations, potentially causing earlier and more severe symptoms.
  • • Women with DM1 have a 50% chance of passing the gene to their children and face high-risk pregnancies that require specialized obstetric care.

Understanding the biology of Myotonic Dystrophy Type 1 (DM1) can help demystify the wide range of symptoms you may experience. At its core, DM1 is caused by a specific “glitch” in the DMPK gene located on chromosome 19 [1].

The Biological “Glitch”: CTG Repeats

Everyone has a section of the DMPK gene where three DNA building blocks—Cytosine, Thymine, and Guanine (CTG)—repeat themselves [1][2]. In most people, this section is short. However, in people with DM1, this section expands and repeats many more times than it should [3].

Understanding the Numbers

Your genetic report will typically provide a number representing how many times this CTG sequence repeats. Doctors use these thresholds to confirm a diagnosis:

  • Normal (5–35 repeats): This is the range found in the general population [4].
  • Premutation (36–50 repeats): Individuals in this range do not usually have symptoms but can pass an expanded, potentially symptomatic version to their children [4].
  • Pathogenic (Over 50 repeats): A repeat count of 50 or higher is considered a positive diagnosis for DM1 [4][5].

Toxic RNA and “Spliceopathy”

The way this expansion causes disease is unique. When your body tries to use the DMPK gene, it creates a “messenger” molecule called RNA. Because of the expansion, this RNA becomes “toxic” [6][7].

These toxic RNA molecules get “stuck” inside the cell nucleus, acting like a magnet that traps essential proteins. When these proteins are trapped, the cell can no longer “edit” other genetic instructions correctly. This state of widespread mis-editing—known as spliceopathy—prevents cells across multiple organs from functioning normally [8][9]. Because the expanded RNA actively causes harm by trapping proteins rather than just being missing, this is known as a toxic gain-of-function [6].

Genetic Anticipation

One of the most complex parts of DM1 is genetic anticipation. This is a phenomenon where the CTG repeat expansion tends to get larger as it is passed from one generation to the next [10][3]. As the repeat size increases, symptoms often appear earlier in life and may be more severe [11][5].

  • Maternal Bias in Congenital DM1: The most severe form of the disease, Congenital DM1 (present at birth), is almost exclusively passed from an affected mother to her child [12][13]. This is likely due to the way DNA is packaged in eggs compared to sperm [14][15].

Family Planning and Pregnancy

If you are of childbearing age, genetic counseling is highly recommended [16]. Because of the 50% chance of passing the gene to a child, you can discuss reproductive options such as In Vitro Fertilization (IVF) with Preimplantation Genetic Testing (PGT) to ensure the gene is not passed on [17].

Additionally, pregnancy itself carries high risks for a woman with DM1 (such as worsening muscle weakness, myotonia, heart issues, and labor complications), requiring proactive care from a high-risk obstetrician [18].

Completeness Checklist: Your Genetic Report

When you review your genetic report, ensure it contains these key details to provide a full picture for your care team:

  • [ ] Gene Name: Confirms the DMPK gene was tested [1].
  • [ ] Repeat Count: Provides the specific number of CTG repeats (e.g., 250, 600) [19].
  • [ ] Testing Method: Mentions techniques like TP-PCR or Fragment Analysis [4].
  • [ ] Variant Repeats: Notes if any “interruptions” (like CCG) were found, which can sometimes mean a milder course [20][21].
  • [ ] Clinical Correlation: A statement from the lab explaining how your results match your symptoms [22].

Frequently Asked Questions

What does a CTG repeat count over 50 mean on my report?
A CTG repeat count of 50 or higher on your genetic report is considered a positive, pathogenic diagnosis for Myotonic Dystrophy Type 1. A normal range is typically between 5 and 35 repeats.
What is genetic anticipation in DM1?
Genetic anticipation is a process where the CTG repeat expansion gets larger as it is passed from parent to child. As the number of repeats increases, DM1 symptoms often begin earlier in life and can be more severe.
Can DM1 be passed to my children?
Yes, there is a 50% chance of passing the DM1 gene expansion to a child. The most severe form, congenital DM1, is almost exclusively passed from an affected mother to her baby, making family planning and genetic counseling very important.
What are variant repeats or CCG interruptions?
Variant repeats, such as CCG interruptions within the CTG sequence, are slight variations in the genetic expansion. If your report notes these interruptions, it can sometimes indicate a milder course of the disease.
Why is the DMPK gene important in Myotonic Dystrophy?
The DMPK gene provides instructions for making essential cellular components. In DM1, a glitch in this gene creates toxic RNA that traps important proteins, preventing cells in multiple organs from functioning properly—a process called spliceopathy.

Questions for Your Doctor

  • • What was my exact CTG repeat count, and does my report mention any 'variant repeats' like CCG interruptions?
  • • Given my repeat size, what clinical subtype (mild, adult, or childhood-onset) do I currently fall into?
  • • Does my genetic report show any 'methylation' flanking the repeat expansion?
  • • Based on this report, what is the risk for my children or future children, and what testing options are available for them?
  • • Can you refer me to a genetic counselor to discuss family planning and reproductive options?

Questions for You

  • • Have you looked at your genetic report yet, and do you know where to find the CTG repeat number?
  • • Are you aware of the medical history of your parents or grandparents regarding muscle weakness, cataracts, or heart issues?
  • • How does knowing the genetic 'why' behind your symptoms change how you feel about your diagnosis?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Myotonic Dystrophies: A Genetic Overview.

    Soltanzadeh P

    Genes 2022; (13(2)) doi:10.3390/genes13020367.

    PMID: 35205411
  2. 2

    Molecular Diagnosis of Myotonic Dystrophy.

    Chakraborty S, Vatta M, Bachinski LL, et al.

    Current protocols in human genetics 2016; (91()):9.29.1-9.29.19 doi:10.1002/cphg.22.

    PMID: 27727437
  3. 3

    No increase in the CTG repeat size during transmission from parent with expanded allele: false suspicion of contraction phenomenon.

    Goñi Ros N, Sienes Bailo P, González Tarancón R, et al.

    Advances in laboratory medicine 2023; (4(2)):185-194 doi:10.1515/almed-2022-0079.

    PMID: 38075944
  4. 4

    Robust and accurate detection and sizing of repeats within the DMPK gene using a novel TP-PCR test.

    Leferink M, Wong DPW, Cai S, et al.

    Scientific reports 2019; (9(1)):8280 doi:10.1038/s41598-019-44588-3.

    PMID: 31164682
  5. 5

    Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.

    Cerro-Herreros E, González-Martínez I, Moreno-Cervera N, et al.

    Molecular therapy. Nucleic acids 2020; (21()):837-849 doi:10.1016/j.omtn.2020.07.021.

    PMID: 32805487
  6. 6

    Expression levels of core spliceosomal proteins modulate the MBNL-mediated spliceopathy in DM1.

    Louis JM, Frias JA, Schroader JH, et al.

    Human molecular genetics 2024; (33(21)):1873-1886 doi:10.1093/hmg/ddae125.

    PMID: 39180495
  7. 7

    Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1.

    Mishra SK, Hicks SM, Frias JA, et al.

    NAR molecular medicine 2026; (3(1)):ugag007 doi:10.1093/narmme/ugag007.

    PMID: 41710065
  8. 8

    Muscle wasting in myotonic dystrophies: a model of premature aging.

    Mateos-Aierdi AJ, Goicoechea M, Aiastui A, et al.

    Frontiers in aging neuroscience 2015; (7()):125 doi:10.3389/fnagi.2015.00125.

    PMID: 26217220
  9. 9

    Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells.

    Porquet F, Weidong L, Jehasse K, et al.

    Molecular therapy. Nucleic acids 2023; (32()):857-871 doi:10.1016/j.omtn.2023.05.007.

    PMID: 37273786
  10. 10

    DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.

    Tomé S, Gourdon G

    International journal of molecular sciences 2020; (21(2)) doi:10.3390/ijms21020457.

    PMID: 31936870
  11. 11

    The Need for Establishing a Universal CTG Sizing Method in Myotonic Dystrophy Type 1.

    Ballester-Lopez A, Linares-Pardo I, Koehorst E, et al.

    Genes 2020; (11(7)) doi:10.3390/genes11070757.

    PMID: 32645888
  12. 12

    DMPK hypermethylation in sperm cells of myotonic dystrophy type 1 patients.

    Yanovsky-Dagan S, Cohen E, Megalli P, et al.

    European journal of human genetics : EJHG 2022; (30(8)):980-983 doi:10.1038/s41431-021-00999-3.

    PMID: 34776509
  13. 13

    Fetal Brain MRI Findings in Myotonic Dystrophy and Considerations for Prenatal Genetic Testing.

    Shear MA, Penon-Portmann M, Shieh JT, et al.

    Neurology. Genetics 2024; (10(6)):e200171 doi:10.1212/NXG.0000000000200171.

    PMID: 39444647
  14. 14

    CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy.

    Barbé L, Lanni S, López-Castel A, et al.

    American journal of human genetics 2017; (100(3)):488-505 doi:10.1016/j.ajhg.2017.01.033.

    PMID: 28257691
  15. 15

    Myotonic dystrophy type 1 (DM1) clinical subtypes and CTCF site methylation status flanking the CTG expansion are mutant allele length-dependent.

    Morales F, Corrales E, Zhang B, et al.

    Human molecular genetics 2021; (31(2)):262-274 doi:10.1093/hmg/ddab243.

    PMID: 34432028
  16. 16

    Primary amenorrhea in myotonic dystrophy type 1: Initial presentation versus incidental finding on whole genome sequencing.

    Damon J, Chase C, Higashimoto T

    American journal of medical genetics. Part A 2024; (194(9)):e63650 doi:10.1002/ajmg.a.63650.

    PMID: 38709060
  17. 17

    Robust Detection of Somatic Mosaicism and Repeat Interruptions by Long-Read Targeted Sequencing in Myotonic Dystrophy Type 1.

    Mangin A, de Pontual L, Tsai YC, et al.

    International journal of molecular sciences 2021; (22(5)) doi:10.3390/ijms22052616.

    PMID: 33807660
  18. 18

    Case Report: Severe Peripartum Cardiac Disease in Myotonic Dystrophy Type 1.

    Besant G, Bourque PR, Smith IC, et al.

    Frontiers in cardiovascular medicine 2022; (9()):899606 doi:10.3389/fcvm.2022.899606.

    PMID: 35722118
  19. 19

    Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre.

    Khadilkar S, Jagiasi K, Yadav J, et al.

    The Journal of the Association of Physicians of India 2017; (65(6)):32-37.

    PMID: 28782311
  20. 20

    Identification of ZNF850 as a novel CTG repeat expansion-related gene in myotonic dystrophy type 1 patient-derived iPSCs.

    Kamon M, Wakatsuki S, Nakamori M, et al.

    Human molecular genetics 2025; (34(4)):327-337 doi:10.1093/hmg/ddae186.

    PMID: 39679849
  21. 21

    De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1.

    Cumming SA, Hamilton MJ, Robb Y, et al.

    European journal of human genetics : EJHG 2018; (26(11)):1635-1647 doi:10.1038/s41431-018-0156-9.

    PMID: 29967337
  22. 22

    CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.

    Ketley A, Wojciechowska M, Ghidelli-Disse S, et al.

    Science translational medicine 2020; (12(541)) doi:10.1126/scitranslmed.aaz2415.

    PMID: 32350131

This page explains DM1 genetic test results for educational purposes only. A genetic counselor or neurologist is the best source for interpreting your specific CTG repeat count and assessing your family risks.

Stay up to date

Get notified when new research about Steinert myotonic dystrophy is published.

No spam. Unsubscribe anytime.